

# **EXHIBIT 22**

**UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

KING DRUG COMPANY OF FLORENCE, Inc., et al., on behalf of Themselves and all others similarly Situating.  Plaintiffs,  v.  CEPHALON, INC., et al.,  Defendants.	Civil Action No.  2:06-cv-01787-MSG
	Judge Mitchell S. Goldberg

**DECLARATION OF MARGARET M. GLAZIER**

I, Margaret M. Glazier, do declare as follows:

1. I am the Compliance/Regulatory Officer of Burlington Drug Company, Inc. (“Burlington Drug”), a pharmaceutical wholesale business located in Milton, Vermont. I am also a member and officer of Burlington Drug’s Board of Directors. I have personal knowledge of all matters attested to herein and am authorized to execute this declaration on behalf of Burlington Drug.

2. Burlington Drug is a named plaintiff and certified representative of the direct purchaser class in the above-captioned litigation. On May 11, 2006, Burlington Drug executed an engagement letter wherein it retained certain law firms, namely Smith Segura & Raphael, LLP (f/k/a Percy, Smith & Foote, LLP), Odom & DesRoches, LLP, and Garwin, Gerstein & Fisher LLP to represent Burlington Drug in connection with this class action litigation. Burlington Drug has had a long-standing and highly successful relationship with these firms, having dealt with them for many years.

3. As a named plaintiff, Burlington Drug has actively participated in this case from its inception almost ten years ago. Among other things, Burlington Drug has, through various employees, collected and produced documents and transactional data in response to defendants' document requests and, through a corporate designee, answered questions at a deposition taken in January 2011 by defendants' attorneys pursuant to Federal Rule of Civil Procedure 30(b)(6), for which he was ably prepared and represented by Smith Segura & Raphael. I also traveled to Philadelphia in January 2014 and attended a multi-day mediation held before Magistrate Judge Strawbridge in this case. I have been consulted and kept informed about the progress of the case, including the settlement negotiations that eventually resulted in a \$512 million cash settlement with the Cephalon, Barr, and Teva Defendants for the direct purchaser class.

4. I wholeheartedly support final approval of the \$512 million settlement reached between the direct purchaser class and the Cephalon, Barr, and Teva Defendants in this case. I feel this \$512 million settlement obtained by counsel, the largest ever in a delayed generic entry case on behalf of direct purchasers, to be an exceptional result. While I am not a lawyer, I also view the settlement obtained by counsel as an excellent result based on my experience in several other complex litigations.

5. I understand that the attorneys appointed by the Court to represent the class in this litigation intend to submit a request to the Court for an attorneys' fee award equal to one-third of the \$512 million settlement fund (plus accrued interest) and for reimbursement of the expenses they incurred litigating this case. Burlington Drug is a sophisticated business enterprise and understands the risks, time, and expense associated with litigating complex antitrust cases like this one. I fully support Class Counsel's application for an award of attorneys' fees and reimbursement of expenses as requested.


6. Had Burlington Drug retained the law firms and/or attorneys specified in the aforementioned engagement letter to represent it in an individual action, Burlington Drug would have retained these same attorneys based on a 33 1/3% contingency fee in the event of settlement or compromise without trial and/or based on a 40% contingency fee in the event of trial, with any applicable contingency fee percentage computed in addition to out-of-pocket cost and expense.

7. Furthermore, Class Counsel have repeatedly shown themselves to be experienced and highly skilled in achieving significant recoveries for my company and for direct purchasers more generally in cases alleging delayed or impeded generic competition, and other claims. In this case, Class Counsel provided exceptional legal services to Burlington Drug and the other direct purchasers comprising the aggrieved class in this complex case for almost a decade, which was not without substantial risk.

8. The benefit conferred upon the Class of direct purchasers by the settlement negotiated by Class Counsel is significant. Moreover, Class Counsel's requested fee is consistent with the fees that I understand have been awarded to class counsel in similar antitrust cases involving allegations of impeded generic competition in which Burlington Drug has participated as a representative plaintiff or as a class member.

I declare under penalty of perjury under the laws of the United States that the foregoing is true and correct.

Dated: August 25, 2015



---

Margaret M. Glazier  
Compliance/Regulatory Officer  
Burlington Drug Company, Inc.